Adherence to HIV treatment as prevention and preexposure prophylaxis

Biomedical Advances in HIV Prevention: Social and Behavioral Perspectives

Volumn 9781461488453, Issue , 2014, Pages 69-108

  Amico, K Rivet ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904805814     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-8845-3_5     Document Type: Chapter

References (116)

1. Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45(3):372-9. Epub 2011/03/10.
2. Foundation KF. The Global HIV/AIDS Epidemic. Fact Sheet. December 2012.
3. Cohen M. Prevention of HIV-1 infection 2013: glimmers of hope. J Int AIDS Soc. 2012;15 Suppl 4:18066. Epub 2012/12/12.
4. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505. Epub 2011/07/20.
5. Cohen MS, Dye C, Fraser C, Miller WC, Powers KA, Williams BG. HIV treatment as prevention: debate and commentary-will early infection compromise treatment-as-prevention strategies? PLoS Med. 2012;9(7):e1001232. Epub 2012/07/18.
6. Ortego C, Huedo-Medina TB, Llorca J, Sevilla L, Santos P, Rodriguez E, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011;15(7):1381-96. Epub 2011/04/07.
7. Munro S, Lewin S, Swart T, Volmink J.A review of health behaviour theories: how useful are these for developing interventions to promote long-term medication adherence for TB and HIV/AIDS? BMC public health. 2007;7:104. Epub 2007/06/15.
8. Amico KR, Harman JJ, JohnsonBT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996-2004. J Acquir Immune Defic Syndr. 2006;41(3):285-97. Epub 2006/03/17.
9. Bruin M de, Viechtbauer W, Schaalma HP, Kok G, Abraham C, Hospers HJ. Standard care impact on effects of highly active antiretroviral therapy adherence interventions:Ameta-analysis of randomized controlled trials. Arch Intern Med. 2010;170(3):240-50. Epub 2010/02/10.
10. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load.A metaanalytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43 Suppl 1:S23-35. Epub 2006/11/30.
11. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012;156(11):817-33. Epub 2012/03/07.
12. Vernazza P, Hirschel B, Bernasconi E, Flepp M. Les personnes seropositives ne souffrant d'aucune autre MST et suivant un traitement antiretroviral efficace ne transmettent pas le VIH 2 voie sexualle. Bulletin des médecins suisses. 2008;89(5):5.
13. WHO. Programmatic update: Antiretroviral treatment as prevention (TasP) of HIV and TB. WHO/HIV/201212June 2012.
14. Eaton JW, Johnson LF, Salomon JA, Barnighausen T, Bendavid E, Bershteyn A, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9(7):e1001245. Epub 2012/07/18.
15. Kilmarx PH, Mutasa-Apollo T. Patching a leaky pipe: the cascade of HIV care. Curr opin HIV AIDS. 2013;8(1):59-64. Epub 2012/12/06.
16. El-SadrWM, Holmes CB, Mugyenyi P, Thirumurthy H, Ellerbrock T, Ferris R, et al. Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr. 2012;60 Suppl 3:S96-104. Epub 2012/09/14.
17. Mehta M, Semitala F, Lynen L, Colebunders R. Antiretroviral treatment in low-resource settings: what has changed in the last 10 years and what needs to change in the coming years? Expert Rev Anti Infect Ther. 2012;10(11):1287-96. Epub 2012/12/18.
18. Dombrowski JC, Harrington RD, Golden MR. Evidence for the long-term stability of HIV transmission-associated sexual behavior after HIV diagnosis. Sex Transm Dis. 2013;40(1):41-5. Epub 2012/12/21.
19. Goodreau SM, Carnegie NB, Vittinghoff E, Lama JR, Sanchez J, Grinsztejn B, et al. What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)? PloS one. 2012;7(11):e50522. Epub 2012/12/05.
20. Ganguli I, Bassett IV, Dong KL, Walensky RP. Home testing for HIV infection in resourcelimited settings. Curr HIV/AIDS Rep. 2009;6(4):217-23. Epub 2009/10/24.
21. Carballo-Dieguez A, Frasca T, Dolezal C, Balan I. Will gay and bisexually active men at high risk of infection use over-the-counter rapid HIV tests to screen sexual partners? J Sex Res. 2012;49(4):379-87. Epub 2012/02/02.
22. Alemnji G, Nkengasong JN, Parekh BS. HIV testing in developing countries: what is required? Indian J Med Res. 2011;134(6):779-86. Epub 2012/02/09.
23. Chow EP, Wilson DP, Zhang L. The rate of HIV testing is increasing among men who have sex with men in China. HIV medicine. 2012;13(5):255-63. Epub 2012/01/19.
24. Fonner VA, Denison J, Kennedy CE, O'Reilly K, Sweat M. Voluntary counseling and testing (VCT) for changing HIV-related risk behavior 2 developing countries. Cochrane Database Syst Rev. 2012;9:CD001224. Epub 2012/09/14.
25. Hermans L, Wensing A, Hoepelman A, Dutihl J, Mudrikova T. Delayed HIV testing in internal medicine clinics-a missed opportunity. The Netherlands J Med. 2012;70(2):69-73. Epub 2012/03/16.
26. Kaai S, Bullock S, Burchell AN, Major C. Factors that affect HIV testing and counseling services among heterosexuals in Canada and the United Kingdom: an integrated review. Patient edu couns. 2012;88(1):4-15. Epub 2011/12/27.
27. Owen SM. Testing for acute HIV infection: implications for treatment as prevention. Curr opin HIV and AIDS. 2012;7(2):125-30. Epub 2012/02/09.
28. Thornton AC, Delpech V, Kall MM, Nardone A. HIVtesting in community settings in resourcerich countries: a systematic review of the evidence. HIV medicine. 2012;13(7):416-26. Epub 2012/03/15.
29. Tripathy S, Pereira M, Tripathy SP. HIV testing in India. Clini lab med. 2012;32(2):175-91. Epub 2012/06/26.
30. Altice FL, Friedland GH. The era of adherence to HIV therapy. Ann Intern Med. 1998;129(6):503-5. Epub 1998/09/12.
31. Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Ann rev of pharmacol and toxicol. 2012;52:275-301. Epub 2011/09/29.
32. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012;156(11):817-33, W-284, W-5, W-6, W-7, W-8, W-9, W-90, W-91, W-92, W-93, W-94. Epub 2012/03/07.
33. Ammassari A, Lorenzini P, Mussini C, Cozzi-Lepri A, Baldelli F, Gori A, et al. Impact of antiretroviral dosing frequency and daily pill burden on virological success rates in patients of the ICoNA cohort starting their first ART. J Int AIDS Soc. 2012;15(6):18233. Epub 2012/12/14.
34. Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS. 2011;25(3):279-90. Epub 2011/01/18.
35. Osterberg LG, Urquhart J, Blaschke TF. Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther. 2010;88(4):457-9. Epub 2010/09/22.
36. Bassett IV, Wang B, Chetty S, Mazibuko M, Bearnot B, Giddy J, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr. 2009;51(2):135-9. Epub 2009/06/09.
37. Fleishman JA, Yehia BR, Moore RD, Korthuis PT, Gebo KA. Establishment, retention, and loss to follow-up in outpatient HIV care. J Acquir Immune Defic Syndr. 2012;60(3):249-59. Epub 2012/04/26.
38. Ma Y, Zhao D, Yu L, Bulterys M, Robinson ML, ZhaoY, et al. Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis. 2010;50(2):264-71. Epub 2009/12/19.
39. Sayles JN, Rurangirwa J, Kim M, Kinsler J, Oruga R, Janson M. Operationalizing treatment as prevention in Los Angeles County: antiretroviral therapy use and factors associated with unsuppressed viral load in the Ryan White system of care. AIDS Patient Care STDS. 2012;26(8):463-70. Epub 2012/07/11.
40. Yehia BR, Fleishman JA, Metlay JP, Moore RD, Gebo KA. Sustained viral suppression in HIV-infected patients receiving antiretroviral therapy. JAMA. 2012;308(4):339-42. Epub 2012/07/24.
41. Fox MP, Cutsem GV, Giddy J, Maskew M, Keiser O, Prozesky H, et al. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr. 2012;60(4):428-37. Epub 2012/03/22.
42. Simoni JM, Yard SS, Huh D. Prospective prediction of viral suppression and immune response nine months after ART initiation in Seattle, WA. AIDS care. 2013;25(2):181-5. Epub 2012/05/30.
43. Colfax GN. Beliefs about viral load and the risk of HIV transmission and associated sexual risk behavior among San Francisco men who have sex with men. XIV International AIDS Conference; Barcelona, Spain 2002.
44. Lafeuillade A. Eliminating the HIV reservoir. Curr HIV/AIDS Rep. 2012;9(2):121-31. Epub 2012/03/15.
45. Fisher JD, Amico KR, Fisher WA, Harman JJ. The information-motivation-behavioral skills model of antiretroviral adherence 2 its applications. Curr HIV/AIDS Rep. 2008;5(4):193-203. Epub 2008/10/08.
46. Fisher JD, Fisher WA, Amico KR, Harman JJ. An information-motivation-behavioral skills model of adherence 2 antiretroviral therapy. Health Psychol. 2006;25(4):462-73. Epub 2006/07/19.
47. Tarakeshwar N, Srikrishnan AK, Johnson S, Vasu C, Solomon S, Merson M, et al. A social cognitive model of health for HIV-positive adults receiving care in India. AIDS Behav. 2007;11(3):491-504. Epub 2006/10/10.
48. Safren SA, Gonzalez J, Soroudi N. Coping with chronic illness: a cognitive-behavioral therapy approach for adherence and depression: therapist guide (treatments thatwork). Oxford: Oxford University Press; 2008.
49. El-Sadr WM. HPTN065 TLC-Plus: A study to evaluate the feasibility of an enhanced test, link to care, plus treat approach for HIV prevention in the United States (Protocol v2.0). HIV Prevention Trials Network. 2010.
50. Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1-10. Epub 1995/03/01.
51. Mugavero MJ. Improving engagement in HIV care: what can we do? Top HIV Med. 2008;16(5):156-61. Epub 2008/12/25.
52. Amico K. A situated-Information Motivation Behavioral Skills Model of Care Initiation and Maintenance (sIMB-CIM): an IMB model based approach to understanding and intervening in engagement in care for chronic medical conditions. J Health Psychol. 2011;16(7):1071-81. Epub 2011/04/05.
53. Smith LR, Fisher JD, Cunningham CO, Amico KR. Understanding the behavioral determinants of retention in HIV care: a qualitative evaluation of a situated information, motivation, behavioral skills model of care initiation and maintenance. AIDS Patient Care STDS. 2012;26(6):344-55. Epub 2012/05/23.
54. Bartholomew LK, Parcel GS, Kok G. Intervention mapping: a process for developing theoryand evidence-based health education programs. Health Educ Behav. 1998;25(5):545-63. Epub 1998/10/13.
55. Johnson BT, Carey MP, Chaudoir SR, Reid AE. Sexual risk reduction for persons living with HIV: research synthesis of randomized controlled trials, 1993-2004. J Acquir Immune Defic Syndr. 2006;41(5):642-50. Epub 2006/05/03.
56. Amico KR, Orrell C. Antiretroviral therapy adherence support: recommendations and future directions. J Int Assoc Provid AIDS Care. 2013;12(2):128-37. Epub 2013/01/22.
57. Amico KR, Orrell C. ART Adherence Support: Recommendations and Future Directions. J Int Assoc Provid AIDS Care. 2013;in press.
58. Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr infect dis rep. 2008;10(6):515-21. Epub 2008/10/24.
59. Simoni JM, Amico KR, Smith L, Nelson K. Antiretroviral adherence interventions: translating research findings to the real world clinic. Curr HIV/AIDS Rep. 2010;7(1):44-51. Epub 2010/04/29.
60. Dieffenbach CW. Preventing HIV transmission through antiretroviral treatment-mediated virologic suppression: aspects of an emerging scientific agenda. Curr opin HIV and AIDS. 2012;7(2):106-10. Epub 2012/01/10.
61. Forsyth AD, Valdiserri RO. Reaping the prevention benefits of highly active antiretroviral treatment: policy implications of HIV Prevention Trials Network 052. Curr opin HIV and AIDS. 2012;7(2):111-6. Epub 2012/01/10.
62. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410. Epub 2012/07/13.
63. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-99. Epub 2010/11/26.
64. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-34. Epub 2012/07/13.
65. Kelesidis T, Landovitz RJ. Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep. 2011;8(2):94-103. Epub 2011/04/06.
66. Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS. 2011;25(2):63-71. Epub 2011/02/03.
67. Prevention CfDCa. Morbidity and mortality weekly report (MMWR), Interim guidance: Preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb mortal wkly rep. 2011;60(03):4.
68. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-22. Epub 2012/07/13.
69. Amico KR, Liu A, McMahan V, et al. Adherence Indicators and Pre-exposure Prophylaxis (PrEP) Drug Levels in the iPrEx Study. 18th Conference on Retroviruses and Opportunistic Infections (CROI); Boston, US 2011.
70. Anderson PL, Lama J, Buchbinder S, et al. Interpreting detection rates of intracellular emtricitabine-triphosphate (FTC-TP) and tenofovir-diphosphate (TFV-DP) in the iPrEx trial. 18th Conference on Retroviruses and Opportunistic Infections (CROI); Boston, US 2011.
71. Amico KR.Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr opin HIV and AIDS. 2012;7(6):542-8. Epub 2012/09/12.
72. Amico KR, LiuA, Marcus JL, McMahan V, et al. Correlates of Study Product Use Among U.S. Participants in the iPrEx Randomized ControlledTrial of Daily Oral Preexposure Prophylaxis. International AIDS Conference July 2012;Washington, DC 2012.
73. Haberer J. Near perfect early adherence to antiretroviral pre-exposure prophylaxis (PrEP) against HIV infection among HIV-serodiscordant couples as determined by multiple measures: preliminary data from the Partners PrEP study. 18th Conference on Retroviruses and Opportunistic Infections; Boston, US 2011.
74. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabinetenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci transl med. 2012;4(151):151ra25. Epub 2012/09/14.
75. Robert M Grant FvG. HPTN 067: The ADAPT study: A Phase II, Randomized, Open- Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP). 2012.
76. Roy Gulick KM, Timothy W. HPTN 069: NEXT-PREP: Novel Exploration of Therapeutics for PREP: A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC + FTC), Maraviroc + Tenofovir disoproxil fumarate (MVC + TDF), or Tenofovir disoproxil fumarate + Emtricitabine (TDF + FTC) for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV Transmission in At-Risk Men Who Have Sex with Men. 2012 Contract No.: Protocol Version 2.0.
77. Spire BMJ, Aboulker JP, Le Gall JM. Pre-exposure prophylaxis in France: IPERGAY. TasP PrEP evidence summit 2012 (International Association of Physicians inAIDS Care and British HIV Association); June 11-12 2012; London, UK 2012.
78. Administration UFaD. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012 [cited 2012 July]; http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm.
79. Amico KR, Mansoor LE, Corneli A, Torjesen K, Straten A van der. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS and behavior. 2013. Epub 2013/02/26.
80. Ferrer RA, Morrow KM, Fisher WA, Fisher JD. Toward an information-motivation-behavioral skills model of microbicide adherence in clinical trials. AIDS Care. 2010;22(8):997-1005. Epub 2010/06/17.
81. Psaros C. Evaluation and Process Outcomes from an Adherence Intervention to Support HIV Pre-Exposure Prophylaxis (PrEP) Adherence in HIV-Serodiscordant Couples in Uganda. 7th Annual HIV Treatment and Prevention Adherence Conference of the International Association of Providers in AIDS Care; June 2012; Miami, FL 2012.
82. Amico KRMV, Marcus J, Goicochea P, Vargas L, Grant R, Liu A. Integrated Next Step Counseling (iNSC): A discussion based sexual health promotion conversation to support men who have sex with men using PrEP in the iPrEx open label extension. 7th Annual HIV Treatment and Prevention Adherence Conference of the International Association of Providers in AIDS Care; June, 2012; Miami, FL 2012.
83. RA K, McMahan V, Goicochea P, Vargas L, Marcus JL, Grant RM, et al. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav. 2012;16(5):1243-59.
84. Safren SA, Otto MW, Worth JL, Salomon E, Johnson W, Mayer K, et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther. 2001;39(10):1151-62. Epub 2001/10/03.
85. Straten A van der, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13-9. Epub 2012/02/16.
86. Kalichman SC, Pope H, White D, Cherry C, Amaral CM, Swetzes C, et al. Association between health literacy and HIV treatment adherence: further evidence from objectively measured medication adherence. J Int Assoc Physician AIDS Care. 2008;7(6):317-23. Epub 2008/12/06.
87. Mann T, Sherman D, Updegraff J. Dispositional motivations and message framing: a test of the congruency hypothesis in college students. Health Psychol. 2004;23(3):330-4. Epub 2004/04/22.
88. Ferster CB, Culbertson S. Behavior principles (3rd ed). Englewood Cliffs: Prentice-Hall; 1982.
89. Festinger L. A theory of cognitive dissonance. Stanford: Standford University Press; 1957.
90. Rogers RW. A protective motivation theory of fear appeals and attitude change. J Psychol. 1975;91:93-114.
91. Rollnick S, Miller W, Butler CC. Motivational interviewing in health care: helping patients change behavior (applications of Motivational Interviewing). New York: Guilford Press; 2008.
92. Kok G, Mesters I. Getting inside the black box of health promotion programmes using intervention Mapping. Chronic illness. 2011;7(3):176-80. Epub 2011/09/09.
93. Barash EA, Golden M.Awareness and use of HIV pre-exposure prophylaxis among attendees of a seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDS. 2010;24(11):689-91. Epub 2010/09/25.
94. Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee SJ, Leibowitz AA. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS care. 2011;23(9):1136-45. Epub 2011/04/09.
95. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548-55. Epub 2010/06/01.
96. Kegeles SM, Hays RB, Coates TJ. The Mpowerment Project: a community-level HIV prevention intervention for young gay men. Am J Public Health. 1996;86(8):1129-36. Epub 1996/08/01.
97. Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376(9755):1838-45. Epub 2010/11/13.
98. Kop ML, K van der, Gelmon L, et al. In-depth analysis of patient-clinician cell phone communication during theWelTelKenya1 antiretroviral adherence trial. PloS one. 2012;7(9):e46033. Epub 2012/10/11.
99. Bourne C, Knight V, Guy R, Wand H, Lu H, McNulty A. Short message service reminder intervention doubles sexually transmitted infection/HIV re-testing rates among men who have 2 with men. Sex Transm Infect. 2011;87(3):229-31. Epub 2011/02/08.
100. Costa TM da, Barbosa BJ, Gomese CDA, Sigulem D, Fatima MH de, Filho AC, et al. Results of a randomized controlled trial to assess the effects of a mobile SMS-based intervention on treatment adherence in HIV/AIDS-infected Brazilianwomen and impressions and satisfaction with respect to incoming messages. Int J Med Inform. 2012;81(4):257-69. Epub 2012/02/03.
101. Dowshen N, Kuhns LM, Johnson A, Holoyda BJ, Garofalo R. Improving adherence to antiretroviral therapy for youth living with HIV/AIDS: a pilot study using personalized, interactive, daily text message reminders. J Med Internet Res. 2012;14(2):e51. Epub 2012/04/07.
102. Haberer JE, Kiwanuka J, Nansera D, Wilson IB, Bangsberg DR. Challenges in using mobile phones for collection of antiretroviral therapy adherence data in a resource-limited setting. AIDS Behav. 2010;14(6):1294-301. Epub 2010/06/10.
103. Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, Walque D de, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011;25(6):825-34. Epub 2011/01/22.
104. Sidney K, Antony J, Rodrigues R, Arumugam K, Krishnamurthy S, D'Souza G, et al. Supporting patient adherence to antiretrovirals using mobile phone reminders: patient responses from South India. AIDS care. 2012;24(5):612-7. Epub 2011/12/14.
105. Eaton LA, Kalichman S. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep. 2007;4(4):165-72. Epub 2008/03/28.
106. Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS. 2002;16(16):2175-82. Epub 2002/11/01.
107. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons 2 clinical trials. Clin Infect Dis. 2002;34(8):1115-21. Epub 2002/03/27.
108. Cooper D. Treatment optimization in low- and middle-income countries. J Int AIDS Soc. 2012;15 Suppl 4:18080. Epub 2012/12/12.
109. Emamzadeh-Fard S, Fard SE, Seyedalinaghi SA, Paydary K. Adherence to anti-retroviral therapy and its determinants in HIV/AIDS patients: A review. Infect Disord Drug Targets. 2012;12(5):346-56. Epub 2012/09/29.
110. Kalichman SC, Grebler T. Stress and poverty predictors of treatment adherence among people with low-literacy living with HIV/AIDS. Psychosom Med. 2010;72(8):810-6. Epub 2010/08/19.
111. Waite KR, Paasche-Orlow M, Rintamaki LS, Davis TC, Wolf MS. Literacy, social stigma, and HIV medication adherence. J Gen Intern Med. 2008;23(9):1367-72. Epub 2008/06/20.
112. Waldrop-Valverde D, Osborn CY, Rodriguez A, Rothman RL, Kumar M, Jones DL. Numeracy skills explain racial differences in HIV medication management. AIDS Behav. 2010;14(4):799-806. Epub 2009/08/12.
113. Mugglin C, Estill J, Wandeler G, Bender N, Egger M, Gsponer T, et al. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health. 2012. Epub 2012/09/22.
114. MacPherson P, Corbett EL, Makombe SD, Oosterhout JJ van, Manda E, Choko AT, et al. Determinants and consequences of failure of linkage to antiretroviral therapy at primary care level in Blantyre, Malawi: a prospective cohort study. PloS one. 2012;7(9):e44794. Epub 2012/09/18.
115. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-74. Epub 2010/07/21.
116. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Pre-exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Altanta, Gorgia USA 2013.